Seatbelts in CAR therapy: How safe are CARS?

26Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

© 2015 by the authors; licensee MDPI, Basel, Switzerland. T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abat e serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.

Cite

CITATION STYLE

APA

Minagawa, K., Zhou, X., Mineishi, S., & Di Stasi, A. (2015, May 8). Seatbelts in CAR therapy: How safe are CARS? Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph8020230

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free